about
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.Leishmaniasis of the eyelid mimicking an infundibular cyst and review of the literature on ocular leishmaniasis.B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases.PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures.Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' OrbitopathyTherapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic NeuropathyTreatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyNew immunomodulators in the treatment of Graves' ophthalmopathyGraves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis
P50
Q34010116-51B91210-BF8E-46DB-A923-D0F02CE0C122Q35055076-9E5728EF-EF45-4BD1-A6FF-B8739DD281D3Q37647249-7913D7D6-8332-4C37-9534-4529FE68C877Q38848883-0E6F70C0-C901-4306-8BC3-8D1A6AD9927AQ40962257-4DB18712-97AD-4D5F-9EF6-15BE3DC60CDDQ42156382-B231523C-3CAC-4678-B523-AA6C1CD9AB22Q42503142-94A02F9F-67B8-45E2-B323-AFEC2BF00DD2Q43042591-10773B7A-8CED-43E7-81AF-BA08157C12E1Q44463190-3795E38E-771C-4161-8883-57AE215201EAQ46083146-855584D0-72EC-44D8-9E70-A2B6609B7904Q51838635-022DB654-C9EA-4DB4-828E-53A91898583DQ54756129-50774E38-BBB2-492B-A64E-48590EB42E0CQ58109526-81702420-0566-4F79-9946-FE8A96D51430Q58763451-6D2E9C3D-C0F0-4318-8BA6-5E655C3C6C0FQ79546631-BE37589D-7A68-4F6A-AF58-D235B450C4F2Q81097416-5775D32D-5A55-4489-B7BD-3A5CB46873C1Q84148014-5BFB942C-4C6F-4D81-9064-A031645E1664
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicola Currò
@ast
Nicola Currò
@en
Nicola Currò
@es
Nicola Currò
@nl
Nicola Currò
@sl
type
label
Nicola Currò
@ast
Nicola Currò
@en
Nicola Currò
@es
Nicola Currò
@nl
Nicola Currò
@sl
prefLabel
Nicola Currò
@ast
Nicola Currò
@en
Nicola Currò
@es
Nicola Currò
@nl
Nicola Currò
@sl
P1053
J-6342-2015
P106
P21
P31
P3829
P496
0000-0002-6802-0126